DeepMed Research

Cephalexin

Generic Name: Cephalexin

Brand Names: Keflex

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₇N_₃O_₄S

CAS Number: 15686-71-2

Unique Ingredient Identifier: 5SFF1W6677

Background: Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.

Indication: Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.

Associated Conditions: Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis

Clinical Trials

Bioequivalence Study of Cephalexin Tablets 1g

Phase 1

Completed

Conditions: Infections, Respiratory Tract

Interventions: Drug: Cephalexin 1g tablets

First Posted Date: 2013-01-14

Last Posted Date: 2017-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT01767584

Bioequivalence Study of Cephalexin Suspension 125

Phase 1

Completed

Conditions: Infections, Respiratory Tract

Interventions: Drug: Cephalexin 125 mg/5ml

First Posted Date: 2013-01-14

Last Posted Date: 2017-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT01767532

Effects of Treatments on Atopic Dermatitis

Phase 2

Recruiting

Conditions: Skin Diseases, Genetic
Dermatitis, Atopic
Dermatitis
Skin Diseases
Eczema

Interventions: Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Drug: Cephalexin
Drug: Doxycycline
Other: Placebo Sodium hypochlorite
Other: Placebo capsules
Other: Sodium hypochlorite

First Posted Date: 2012-06-29

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Target Recruit Count: 130

Registration Number: NCT01631617

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

Phase 2

Completed

Conditions: Urinary Tract Infection

Interventions: Other: Placebo
Drug: Cefixime
Drug: Cephalexin
Drug: Trimethoprim/Sulfamethoxazole

First Posted Date: 2012-05-10

Last Posted Date: 2020-08-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 717

Registration Number: NCT01595529

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric, Pittsburgh, Pennsylvania, United States

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

Phase 2

Completed

Conditions: Infections, Pediatrics

Interventions: Drug: Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam
Drug: Ceftaroline fosamil
Drug: Cephalexin or Clindamycin or Linezolid

First Posted Date: 2011-07-22

Last Posted Date: 2015-01-13

Lead Sponsor: Forest Laboratories

Target Recruit Count: 163

Registration Number: NCT01400867

Locations: 🇺🇸
Investigational Site - Morgantown, Morgantown, West Virginia, United States
🇬🇪
Investigational Site - Tbilisi 2, Tbilisi, Georgia
🇵🇱
Investigational Site - Bydgoszcz 2, Bydgoszcz, Poland

and more 68 locations

Antibiotic Prophylaxis Before Surgery Versus After Cord Clamping in Elective Cesarean Delivery - a Double-blind, Prospective, Randomized Placebo-controlled Trial

Not Applicable

Completed

Conditions: Elective Cesarean Section

Interventions: Drug: saline solution
Drug: Keflex

First Posted Date: 2010-11-25

Last Posted Date: 2010-11-25

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 1112

Registration Number: NCT01248078

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery

Not Applicable

Conditions: Surgical Site Infection in Obese Women Undergoing C-section

Interventions: Drug: cephalexin & metronidazole
Drug: placebo

First Posted Date: 2010-09-02

Last Posted Date: 2011-11-11

Lead Sponsor: University of Cincinnati

Target Recruit Count: 475

Registration Number: NCT01194115

Locations: 🇺🇸
The Univeristy Hospital, Cincinnati, Ohio, United States

Antibiotic Prophylaxis for Simple Hand Lacerations

Not Applicable

Terminated

Conditions: Simple Hand Lacerations

Interventions: Drug: cephalexin
Drug: placebo
Drug: clindamycin

First Posted Date: 2010-07-01

Last Posted Date: 2014-11-07

Lead Sponsor: State University of New York - Downstate Medical Center

Target Recruit Count: 73

Registration Number: NCT01155154

Locations: 🇺🇸
Kings County Hospital Center, Brooklyn, New York, United States
🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸
State University of New York, Downstate Medical Center, Brooklyn, New York, United States

Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension

Phase 1

Completed

Conditions: Anti-Infective Agents

Interventions: Drug: Cephalexin suspension (Optocef, BAYO5448 )
Drug: Cephalexin suspension (Keflex)

First Posted Date: 2010-04-16

Last Posted Date: 2014-05-20

Lead Sponsor: Bayer

Target Recruit Count: 26

Registration Number: NCT01105208

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension

Phase 1

Completed

Conditions: Anti-Infective Agents

Interventions: Drug: Cephalexin suspension (Optocef, BAYO5448)
Drug: Cephalexin suspension (Keflex)

First Posted Date: 2010-02-23

Last Posted Date: 2014-04-03

Lead Sponsor: Bayer

Target Recruit Count: 26

Registration Number: NCT01073540

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy